Skip to main content
SpringerLink
Log in

Advances in Bleomycin Studies

  • Chapter
Bleomycin: Chemical, Biochemical, and Biological Aspects

Abstract

The clinical effect of bleomycin was first observed in the treatment of squamous cell carcinomas in 1966. The size of this kind of tumor decreases with bleomycin treatment and even cases of complete cure have been reported. Among the tumors belonging to this group, the well-differentiated type responds to bleomycin treatment with a very high frequency. There are patients who have lived more than 10 years after several courses of treatment with bleomycin alone. The rate of cure from squamous cell carcinoma has been increased by the simultaneous use of bleomycin and radiation or by applying radiation after bleomycin treatment. Most Hodgkin’s lymphomas are very sensitive to bleomycin treatment. This tumor decreases in size rapidly with such treatment, and complete cures have been obtained by a combination of bleomycin with other antitumor agents. Even a daily dose of bleomycin as small as 1 mg exhibits a therapeutic effect on Hodgkin’s lymphoma. Recently, treatment by a combination of bleomycin and a Vinca alkaloid or a platinum compound was found to have a therapeutic effect on testis tumors. Bleomycin treatment does not suppress immune function and does not damage bone marrow; however, the amount of bleomycin used in one course of treatment is presently limited to 200-300 mg per person because of its pulmonary toxicity. Therefore, a bleomycin with lower pulmonary toxicity could exhibit stronger therapeutic action against the tumors described above than the bleomycin presently employed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. S.K., Carter, T., Ichikawa, G. Mathe, and H., Umezawa,Fundamental and clinical studies of bleomycin. GANN Monograph on Cancer Research, No. 19 (Japanese Cancer Association), University of Tokyo Press (1976).

    Google Scholar 

  2. K., Maeda, H., Kosaka, K., Yagishita, and H., Umezawa, J. Antibiot. (Tokyo), Ser. A, 9, 82 (1956).

    Google Scholar 

  3. W.T., Bradner and M.H., Pindell, Nature (London), 196,682 (1962).

    Article  CAS  Google Scholar 

  4. H., Umezawa, M., Hori, M., Ishizuka and T., Takeuchi, J. Antibiot. (Tokyo), Ser. A, 15, 274 (1962).

    CAS  Google Scholar 

  5. N., Tanaka, H., Yamaguchi, and H., Umezawa, J. Antibiot. (Tokyo), Ser. A, 16, 86 (1963).

    Google Scholar 

  6. M., Ishizuka, H., Takayama, T., Takeuchi, and H., Umezawa, J. Antibiot. (Tokyo), Ser. A, 19, 260 (1966).

    CAS  Google Scholar 

  7. M., Ikekawa, F., Iwami, H., Hiranaka, and H., Umezawa, J. Antibiot. (Tokyo), Ser., A, 17, 194(1964).

    CAS  Google Scholar 

  8. H. Umezawa, K. Maeda, T. Takeuchi, and Y. Okami, J. Antibiot, (Tokyo), Ser. A, 19, 200 (1966).

    CAS  Google Scholar 

  9. M., Ishizuka, H., Takayama, T., Takeuchi, and H., Umezawa, J. Antibiot. (Tokyo), Ser. A, 20, 15 (1967).

    CAS  Google Scholar 

  10. H., Umezawa, Y., Suhara, T., Takita, K., Maeda, J. Antibiot (Tokyo), Ser. A, 19,210 (1966).

    CAS  Google Scholar 

  11. H., Umezawa, M., Ishizuka, K., Kimura, J., Iwanaga, and T., Takeuchi, J. Antibiot. (Tokyo), 21, 592 (1968).

    CAS  Google Scholar 

  12. H., Umezawa, Pure Appl. Chem., 28, 665 (1971).

    Article  PubMed  CAS  Google Scholar 

  13. H. Umezawa, Fundamental and clinical studies of bleomycin. GANN Monograph on Cancer Research, No. 19 (Japanese Cancer Association), University of Tokyo Press, PP. 3–36 (1976).

    Google Scholar 

  14. T., Takita, Y., Muraoka, T., Yoshioka, A., Fujii, K., Maeda, and H., Umezawa, J. Antibiot. (Tokyo), 25, 755 (1972).

    CAS  Google Scholar 

  15. H., Naganawa, Y., Muraoka, T., Takita, H., Umezawa, J. Antibiot. (Tokyo), 30, 388 (1977).

    CAS  Google Scholar 

  16. Y., Muraoka, A., Fujii, T., Yoshioka, T, Takita, and H., Umezawa, J. Antibiot. (Tokyo), 30, 178 (1977).

    CAS  Google Scholar 

  17. T., Takita, Y., Muraoka, A., Fujii, H., Itoh, K., Maeda, and H., Umezawa, J. Antibiot. (Tokyo), 25, 197 (1972).

    CAS  Google Scholar 

  18. H., Nakamura, T., Yoshioka, T., Takita, H., Umezawa, Y., Muraoka, and Y., Iitaka, J. Antibiot. (Tokyo), 29, 762 (1976).

    CAS  Google Scholar 

  19. J.H., Coats and J., Roeser,J. Bacteriol., 105, 880 (1971).

    PubMed  CAS  Google Scholar 

  20. Y., Muraoka, H., Kobayashi, A., Fujii, M., Kunishima, T., Fujii, Y.,akayama, T., Takita, and H., Umezawa, J. Antibiot. (Tokyo), 29, 853 (1976).

    Google Scholar 

  21. J.C., Dabrowiak, F.T., Greenaway, W.E., Longo, M., VanHusen, and S.T., Crooke, Biochim. Biophys. Acta,517 , 517 (1978).

    PubMed  CAS  Google Scholar 

  22. A., Falaschi and A., Kornberg, Fed. Proc., 23, 940 (1964).

    PubMed  CAS  Google Scholar 

  23. K., Nagai, H., Suzuki, N., Tanaka, and H., Umezawa, J. Antibiot. (Tokyo), 22, 569 (1969).

    CAS  Google Scholar 

  24. K., Nagai, H., Suzuki, N., Tanaka, and H., Umezawa, J. Antibiot. (Tokyo), 22, 624 (1969).

    CAS  Google Scholar 

  25. K. Nagai, H. Suzuki, N. Tanaka, and H. Umezawa, J. Antibiot. (Tokyo), Biophys. Acta, 179, 165 (1969).

    Google Scholar 

  26. H., Umezawa, H., Asakura, and M., Hori, J. Antibiot. (Tokyo), 26, 521 (1973).

    CAS  Google Scholar 

  27. H., Asakura, M., Hori, and H., Umezawa, J. Antibiot. (Tokyo), 28, 587 (1975).

    Google Scholar 

  28. C.W., Haidle, Mol. Pharmacol., 7, 645 (1971).

    PubMed  CAS  Google Scholar 

  29. C.W., Haidle, M.T., Kuo, and K.K., Weiss, Biochem. Pharmacol., 21, 3308 (1972).

    Article  PubMed  CAS  Google Scholar 

  30. C.W., Haidle, K.K.,Weiss, and M.T., Kuo,Mol. Pharmacol., 8, 531(1972).

    PubMed  CAS  Google Scholar 

  31. C.W., Haidle, K.K., Weiss, and M.L.,MaceJr., Biochem. Biophys. Res. Commun., 48, 1179 (1972).

    Article  PubMed  CAS  Google Scholar 

  32. M.T., Kuo and C.W., Haidle, Biochim. Biophys. Acta, 335, 109 (1973); Biophys. J., 13, 1296 (1973).

    CAS  Google Scholar 

  33. W.E.G., Müller, Z., Yamazaki, H., Breter, and R.K., Zahn, Eur. J. Biochem., 31, 518(1972).

    Article  PubMed  Google Scholar 

  34. W.E.G., Müller, Z., Yamazaki, and R.K., Zahn, Biochem. Biophys. Res. Commun., 46, 1667 (1972).

    Article  PubMed  Google Scholar 

  35. W.E.G., Müller, Z., Yamazaki, J.E., Zoellner, and R.K., Zahn, FEBS Lett., 31, 217 (1973).

    Article  PubMed  Google Scholar 

  36. Z. Yamazaki, W.E.G. Müller, and R.K. Zahn, Biochim. Biophys. Acta, 308, 412 (1973).

    Google Scholar 

  37. S.L., Ross and R.E., Moses, Biochemistry, 17, 581(1978).

    Article  PubMed  CAS  Google Scholar 

  38. M., Chien, A.P., Grollman, and S.B., Horowitz, Biochemistry, 16, 3641(1977).

    Article  CAS  Google Scholar 

  39. E.A., Sausville, J., Peisach, and S.B.,Horowitz, Biochem. Biophys. Res. Commun., 73,814(1976).

    Article  PubMed  CAS  Google Scholar 

  40. J. Bearden and C.W. Haidle, Biochem. Biophys. Res. Commun., 65,371(1975).

    Google Scholar 

  41. W.E.G., Müller, H.J., Rohde, R., Steffen, A., Maidhof, and R.K., Zahn, Cancer Lett., 1. 127 (1976).

    Article  Google Scholar 

  42. Y. Yagoda and H. Krakoff, Fundamental and clinical studies on bleomycin. GANN Monograph on Cancer Research, No. 19 (Japanese Cancer Association), University of Tokyo Press, pp. 255–268 (1976).

    Google Scholar 

  43. T., Ichikawa, A., Matsuda, K., Yamamoto, M., Tsubosaki, T., Kaihara, K., Sakamoto, and H, Umezawa, J. Antibiot. (Tokyo), Ser. A, 20, 149 (1967).

    CAS  Google Scholar 

  44. H., Umezawa, T., Takeuchi, S., Hori, T., Sawa, M., Ishizuka, T., Ichikawa, and T., Komai, J. Antibiot. (Tokyo), 25, 409 (1972).

    CAS  Google Scholar 

  45. H., Umezawa, Lloydia, 40, 67 (1977).

    PubMed  CAS  Google Scholar 

  46. M., Kanao, S. ,Tomita, S., Ishihara, A., Murakami, and H., Okada, Chemotherapy, 21, 1305 (1973).

    CAS  Google Scholar 

  47. K., Takahashi, O., Yoshioka, A., Matsuda, and H., Umezawa, J. Antibiot. (Tokyo), 30, 861 (1977).

    CAS  Google Scholar 

  48. A.,Kono, Chern. Pharm. Bull. (Tokyo), 25, 2882 (1977).

    CAS  Google Scholar 

  49. H., Umezawa, Y., Takahashi, A. Fujii, T., Saino, and T., Takita, J. Antibiot. (Tokyo), 26, 117 (1973).

    CAS  Google Scholar 

  50. T., Takita, A., Fujii, T., Fukuoka, and H., Umezawa,J. Antibiot. (Tokyo), 26, 252 (1973).

    CAS  Google Scholar 

  51. M., Konishi, K., Saito, K., Numata, T., Tsuno, K., Asama, H., Tsukiura, T., Naito, and H., Kawaguchi, J. Antibiot. (Tokyo) J. Antibiot. (Tokyo), 30, 789 (1977)

    Google Scholar 

Download references

Authors
  1. Hamao Umezawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Mass., 02139, USA

    Sidney M. Hect

Rights and permissions

Reprints and permissions

Copyright information

© 1979 Springer-Verlag New York Inc.

About this chapter

Cite this chapter

Umezawa, H. (1979). Advances in Bleomycin Studies. In: Hect, S.M. (eds) Bleomycin: Chemical, Biochemical, and Biological Aspects. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-6191-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-6191-9_2

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-6193-3

  • Online ISBN: 978-1-4612-6191-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation